Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

YYB 103

Next Previous
Drug Profile

YYB 103

Alternative Names: CLM-103; YYB103

Latest Information Update: 02 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yooyoung Pharmaceutical
  • Developer CellabMED; Yooyoung Pharmaceutical
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Glioblastoma
  • Preclinical Solid tumours
  • Discontinued Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Sep 2024 Preclinical trials in Solid tumours in South Korea (IV), prior to September 2024 (CellabMED pipeline, September 2024)
  • 22 Sep 2022 Discontinued - Preregistration for Amyotrophic lateral sclerosis in South Korea (unspecified route)
  • 18 Jul 2022 Phase-I clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in South Korea (IV) (NCT05540873)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top